Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Vaginal artesunate quells CIN 2/3 lesions, clears HPV

Key clinical point: Artesunate vaginal inserts may prevent cervical cancer in some patients with cervical intraepithelial neoplasia 2/3.

Major finding: Of 28 evaluable patients, 19 (67.9%) had histologic regression of lesions, and 9 of those (47.4%) had clearance of human papillomavirus genotypes.

Study details: Phase 1 trial of 29 women with cervical intraepithelial neoplasia 2/3.

Disclosures: Frantz Viral Therapeutics supplied the artesunate vaginal inserts and partial financial support for the study. Dr. Trimble disclosed relationships with a range of companies and organizations outside this work.

Citation:

Trimble CL et al. SGO 2020, Abstract LBA 1.